Qiagen launches panel, software for blood cancers

Create PDF

The new workflow for QCI Interpret was designed to consider the heterogeneous nature of myeloid malignancies and provides actionable information for the subclassification and prognostic assessment of hematological malignancies. QCI Interpret is a web-based clinical decision support platform that draws on the company’s Knowledge Base to evaluate genomic variants in the context of published biomedical literature, professional association guidelines, publicly and privately available databases, drug labels, and clinical trials. The software ranks data according to the highest level of evidence based on actionability tiers from the 2017 AMP/ASCO/CAP guidelines.